Compare Firy Inc. (FIRY) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Firy Inc. vs Recursion Pharmaceuticals Inc — how do they compare? Firy Inc. trades at $10.31 (market cap $163.57M), while Recursion Pharmaceuticals Inc trades at $3.36 (market cap $1.78B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 10.9× Firy Inc.'s market cap, and Firy Inc. is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| FIRY | RXRX | |
|---|---|---|
Market Cap | $163.57M | $1.78B |
Sector | Consumer Cyclical | Health |
52-Week High | $12.45 | $6.79 |
52-Week Low | $2.28 | $2.84 |
Enterprise Value | $107.24M | $1.30B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIRY stock trades at $10.45, up 4.5% today, with a bullish technical signal from moving averages. The company shows improving revenue trends ($104.5M in 2025, projected to $112M in 2026) but continues to post significant losses (-$70.4M net income). Recent developments include a successful $719M legal victory and corporate rebranding from Skillz Inc. Analyst sentiment is mixed with 20% buy, 60% hold, and 20% sell ratings.
While technical indicators suggest near-term upside potential, fundamental challenges persist with negative profitability metrics and cash burn. The stock presents speculative appeal based on legal wins and revenue stabilization, but requires careful risk management given ongoing losses and negative cash flow trends.
RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.
Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Firy Inc.
Firy Inc. operates a mobile gaming platform in the United States, Israel, China, Malta, Hong Kong, Cyprus, and other international markets. The company operates through two segments: Skillz and RZR. Its Skillz platform enables game developers to monetize their content by integrating real-money tournaments, virtual prizes, and social competition features directly into multiplayer games.
Read more on FIRY →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
